LumiraDx Limited (LMDXF)

OTCMKTS: LMDXF · Delayed Price · USD
0.0204
+0.0029 (16.57%)
May 22, 2024, 4:00 PM EDT - Market closed
Market Cap 246.51M
Revenue (ttm) 126.52M
Net Income (ttm) -338.04M
Shares Out 319.00M
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 410,556
Open 0.0200
Previous Close 0.0175
Day's Range 0.0160 - 0.0220
52-Week Range 0.0070 - 0.0290
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About LMDXF

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnos... [Read more]

Sector Healthcare
Founded 2014
Employees 1,210
Stock Exchange OTCMKTS
Ticker Symbol LMDXF
Full Company Profile

Financial Performance

In 2022, LumiraDx's revenue was $254.48 million, a decrease of -39.62% compared to the previous year's $421.43 million. Losses were -$447.79 million, 343.7% more than in 2021.

Financial Statements

News

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securiti...

4 months ago - GlobeNewsWire

Roche to buy part of LumiraDx diagnostics platform for $295 million

Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.

Other symbols: RHHBY
5 months ago - Reuters

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators ...

5 months ago - GlobeNewsWire

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of T...

7 months ago - GlobeNewsWire

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: EVLOGBIOSPRB
7 months ago - Benzinga

LumiraDx Reports Second Quarter 2023 Results

LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended Jun...

9 months ago - GlobeNewsWire

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on...

10 months ago - GlobeNewsWire

LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests

Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional N...

10 months ago - GlobeNewsWire

LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test

LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraD...

11 months ago - GlobeNewsWire

LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has received validation for use by the MHRA under the CTDA process for the LumiraDx SARS-CoV-2 Ag Ultr...

1 year ago - GlobeNewsWire

LumiraDx Reports First Quarter 2023 Results

LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March...

1 year ago - GlobeNewsWire

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16

LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on T...

1 year ago - GlobeNewsWire

LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that i...

1 year ago - GlobeNewsWire

LumiraDx Announces Strategic Refocus and Cost Restructuring Program

LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Res...

1 year ago - GlobeNewsWire

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full...

1 year ago - GlobeNewsWire

LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 f...

1 year ago - GlobeNewsWire

LumiraDx to Present at Raymond James Institutional Investors Conference

LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institu...

1 year ago - GlobeNewsWire

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has rega...

1 year ago - GlobeNewsWire

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of car...

1 year ago - GlobeNewsWire

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it...

1 year ago - GlobeNewsWire

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries Company receives $14.2M in grants fr...

1 year ago - GlobeNewsWire

Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” LumiraDx shares these and other findings from its second annual U.S. survey ...

1 year ago - GlobeNewsWire

Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings

LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View” LumiraDx shares these and other findings from its first annual U.K. survey “Po...

1 year ago - GlobeNewsWire

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa  Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of...

1 year ago - PRNewsWire

LumiraDx Reports Third Quarter 2022 Results

Progress on Near-Term Growth Opportunities and Cost Savings Progress on Near-Term Growth Opportunities and Cost Savings

1 year ago - GlobeNewsWire